Insider Trading Alert - LCI, POWI And LGND Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 20, 2014, 164 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $87.78 to $643,360,199,551.68.

Highlighted Stocks Traded by Insiders:

Lannett Company (LCI) - FREE Research Report

Drabik David A who is Director at Lannett Company sold 10,000 shares at $44.54 on Feb. 20, 2014. Following this transaction, the Director owned 23,750 shares meaning that the stake was reduced by 29.63% with the 10,000-share transaction.

The shares most recently traded at $44.64, up $0.10, or 0.22% since the insider transaction. Historical insider transactions for Lannett Company go as follows:

  • 4-Week # shares bought: 500
  • 12-Week # shares bought: 8,600
  • 24-Week # shares bought: 8,600

The average volume for Lannett Company has been 390,700 shares per day over the past 30 days. Lannett Company has a market cap of $1.6 billion and is part of the health care sector and drugs industry. Shares are up 37.34% year-to-date as of the close of trading on Thursday.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company has a P/E ratio of 78.5. Currently there are 5 analysts that rate Lannett Company a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LCI - FREE

TheStreet Quant Ratings rates Lannett Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Lannett Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Power Integrations (POWI) - FREE Research Report

Brathwaite Nicholas who is Director at Power Integrations sold 9,352 shares at $59.48 on Feb. 20, 2014. Following this transaction, the Director owned 11,781 shares meaning that the stake was reduced by 44.25% with the 9,352-share transaction.

The shares most recently traded at $59.95, up $0.47, or 0.78% since the insider transaction. Historical insider transactions for Power Integrations go as follows:

  • 4-Week # shares sold: 27,153
  • 12-Week # shares sold: 39,127
  • 24-Week # shares sold: 45,229

The average volume for Power Integrations has been 221,200 shares per day over the past 30 days. Power Integrations has a market cap of $1.8 billion and is part of the technology sector and electronics industry. Shares are up 5.79% year-to-date as of the close of trading on Thursday.

Power Integrations, Inc. designs, develops, manufactures, and markets analog and mixed-signal integrated circuits (ICs), and other electronic components and circuitry used in high-voltage power conversion. The stock currently has a dividend yield of 0.68%. The company has a P/E ratio of 31.4. Currently there are 4 analysts that rate Power Integrations a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on POWI - FREE

TheStreet Quant Ratings rates Power Integrations as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Power Integrations Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Ligand Pharmaceuticals (LGND) - FREE Research Report

Bvf Partners L P/Il who is 10% Owner at Ligand Pharmaceuticals sold 422,900 shares at $73.81 on Feb. 20, 2014. Following this transaction, the 10% Owner owned 79,390 shares meaning that the stake was reduced by 84.19% with the 422,900-share transaction.

The shares most recently traded at $74.32, up $0.51, or 0.69% since the insider transaction. Historical insider transactions for Ligand Pharmaceuticals go as follows:

  • 4-Week # shares bought: 293
  • 4-Week # shares sold: 6,000
  • 12-Week # shares bought: 293
  • 12-Week # shares sold: 12,000
  • 24-Week # shares bought: 293
  • 24-Week # shares sold: 12,499

The average volume for Ligand Pharmaceuticals has been 384,100 shares per day over the past 30 days. Ligand Pharmaceuticals has a market cap of $1.5 billion and is part of the health care sector and drugs industry. Shares are up 38.94% year-to-date as of the close of trading on Thursday.

Ligand Pharmaceuticals Incorporated, a biotechnology company, engages in the acquisition and development of royalty revenue generating assets in the United States. The company has a P/E ratio of 80.6. Currently there are 4 analysts that rate Ligand Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LGND - FREE

TheStreet Quant Ratings rates Ligand Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Ligand Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Mesoblast Soars on Stem-Cell Treatment Data

Mesoblast Soars on Stem-Cell Treatment Data

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone